Clearmind enrolls first AUD patients in CMND-100 trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Clearmind enrolls first AUD patients in CMND-100 trial

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

September 11, 2026 8:00 AM EDT

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced the enrollment of the first patients with Alcohol Use Disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the Companys proprietary psychedelic-based treatment candidate for AUD.

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated... More